NeurAxis (NRXS) specializes in neuromodulation therapies, targeting chronic abdominal pain in pediatric and adult patients. NRXS exhibits exceptional technical momentum with shares trading at new all-time...
Shares of NeurAxis, Inc. NRXS have lost 0.8% since the company reported its earnings for the quarter ended June 30, 2025. This compares unfavorably with the S&P 500 Index’s 1.2% gain during the same...
Shares of NeurAxis, Inc. NRXS have gained 13.3% since the company reported its earnings for the quarter ended March 31, 2025. This compares to the S&P 500 Index’s 4.3% growth over the same time frame....
Shares of NeurAxis, Inc. NRXS have gained 0.9% since the company reported earnings for the quarter ended Dec. 31, 2024. This compares favorably to the S&P 500 Index, which declined 0.1% over the same time...
Shares of NeurAxis, Inc. NRXS have gained 41.2% since it reported earnings for the quarter ended Sept. 30, 2024. This strong performance contrasts with the S&P 500 index, which saw a decline of 0.9% during...
Zacks Investment Research has recently initiated coverage of NeurAxis, Inc. NRXS, assigning a "Neutral" recommendation to the company's shares. This assessment comes amid a mixed outlook for the company,...
Today highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field ...